Literature DB >> 11566443

High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane.

A C McDonnel1, W J Murdoch.   

Abstract

Urokinase plasminogen activator (uPA) has been implicated in the metastatic potential of ovarian carcinomas of surface epithelial origin. The SKOV-3 human ovarian cancer cell line was tested for uPA secretory responses (enzyme immunoassay of conditioned media) after treatments with sex steroids, human menopausal gonadotropins (hMG), or gonadotropin-releasing hormone (GnRH). Secretion of uPA during a 6-h incubation was unaffected by testosterone, estradiol-17beta, hMG, or GnRH. Progesterone, at supraphysiological concentrations, suppressed uPA secretion; this reaction was not altered by the progesterone receptor antagonist RU486 or the transcriptional inhibitor actinomycin D. It appears that progesterone exerted a direct biophysical effect on the plasma membrane manifested by an interference with shedding of uPA in exocytotic vesicles. Finally, invasion of SKOV-3 cells into Matrigel was inhibited by progesterone. We suggest that progesterone can disrupt the fluid dynamics of plasma membranes and thereby invoke an antitumorigenic action via inhibition of proteolytic secretions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566443     DOI: 10.1016/s0960-0760(01)00081-4

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Estrous cycle modulates ovarian carcinoma growth.

Authors:  Guillermo N Armaiz-Pena; Lingegowda S Mangala; Whitney A Spannuth; Yvonne G Lin; Nicholas B Jennings; Alpa M Nick; Robert R Langley; Rosemarie Schmandt; Susan K Lutgendorf; Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

2.  Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.

Authors:  William J Murdoch; Edward A Van Kirk; Dale D Isaak; Youqing Shen
Journal:  Gynecol Oncol       Date:  2008-05-20       Impact factor: 5.482

3.  Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion.

Authors:  Chien-Lin Chen; Lydia W T Cheung; Man-Tat Lau; Jung-Hye Choi; Nelly Auersperg; Hsin-Shih Wang; Alice S T Wong; Peter C K Leung
Journal:  Endocrine       Date:  2007-06       Impact factor: 3.633

4.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

5.  Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Authors:  Chelsea R Tieszen; Alicia A Goyeneche; BreeAnn N Brandhagen; Casey T Ortbahn; Carlos M Telleria
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

Review 6.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

7.  Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway.

Authors:  Yan Li; Yi Jiang; Yicong Wan; Lin Zhang; Weiwei Tang; Jingjing Ma; Shan Wu; Wenjun Cheng
Journal:  J Biomed Res       Date:  2012-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.